7 July 2025
Oxford BioTherapeutics announces third oncology drug candidate from Boehringer Ingelheim collaboration selected to advance into IND-enabling studies
• Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford BioTherapeutics’ proprietary OGAP®-Verify discovery platform … • OBT receives milestone payment associated with advance of drug candidate … Oxford, UK and San...
23 June 2025
Monument Therapeutics reports positive Phase I results for novel cognitive impairment in schizophrenia treatment
Manchester, UK, 23 June 2025 - Monument Therapeutics, a precision neuroscience company, today announced positive topline results from its Phase I clinical trial evaluating MT1988, a novel treatment targeting cognitive impairment associated with schizophrenia (CIAS). MT1988 is a...
21 May 2025
INFEX Therapeutics agrees collaboration with Asian clinical trials network, ADVANCE-ID
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces that it has signed a memorandum of understanding (MOU) (the “Collaboration”) with ADVANCE-ID, a clinical trials network comprising over 100 hospitals in Asia, to investigate...
7 May 2025
QV Bioelectronics awarded £1.26m to advance studies on new brain cancer treatment
QV Bioelectronics, developer of an implanted Electric Field Therapy (EFT) device for brain tumours, has announced it has been awarded a £1.26m grant under the Biomedical Catalyst programme. The funding will support key technical and regulatory milestones to prepare for QV’s...
28 April 2025
Monument Therapeutics announces appointment of Robert Radie as Chair and Heather Preston to Advisory Board
Monument Therapeutics, a precision neuroscience company focused on the development of innovative treatments for serious central nervous system disorders (CNS), today announced two key leadership appointments. Robert S. Radie (Bob) has been appointed Non Executive Chair of the...
8 April 2025
Maxwellia appoints Alexandra Trehane as Chief Operating Officer as company sets to scale
Alderley Park, UK – April 7 2025 – Maxwellia, the pioneering consumer healthcare company dedicated to widening access to medicines, is pleased to announce the appointment of Alexandra Trehane as Chief Operating Officer. Alexandra brings extensive experience in operations...
24 March 2025
Oxford BioTherapeutics enters into a strategic collaboration with Roche to discover novel targets for antibody-based therapeutics for the treatment of cancer
• Collaboration leverages OBT’s proprietary OGAP®-Verify discovery platform and Roche’s drug development expertise to advance multiple selected novel oncology targets … • OBT to receive up to US$36 million upfront payments and may be eligible to receive milestone payments...
20 March 2025
GM&C Life Sciences Fund announces £100m+ in matched private sector investment for Greater Manchester, Cheshire and Warrington
Alderley Park, UK, 19th March 2025 – The GM&C Life Sciences Fund, managed by Catapult Ventures, has announced that to date it has leveraged over £100m in private sector life science co-investment. Managed by Catapult Ventures, the GM&C Life Sciences Fund is a seed and...
26 February 2025
Monument Therapeutics secures £850k to advance breakthrough schizophrenia treatment
Manchester, 25th February 2025 — Monument Therapeutics, an innovative neuroscience company applying digital biomarkers to psychiatric drug development, has secured £850k in further funding led by ACF Investors, with participation from Wren Capital, o2h Ventures, and angel...
25 February 2025
Infex signs exclusive license agreement with Venus Remedies Ltd to advance MET-X through clinical development and commercialisation in India
Alderley Park, Cheshire, U.K. Infex Therapeutics, a leading anti-infectives specialist, announces that it has signed an exclusive license agreement for the Indian market (the “Agreement”) with Venus Remedies Ltd (NSE: VENUSREM BSE: 526953) (“Venus Remedies”), an Indian...